AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01502956 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InterStim® device
Description: Eligible subjects will complete baseline assessments, be randomized and scheduled for first stage lead placement (FSLP) InterStim®. The criterion for an initial clinical response to InterStim® therapy will be defined as a ≥50% improvement in the mean number of UUIE/day on a minimum 3 day bladder diary, completed during the 7-14 days following the first stage lead placement (FSLP). Subjects with a ≥ 50% improvement mean number of UUIE/day will be eligible to proceed with implantation of the implantable pulse generator (IPG). Subjects will then be followed monthly to determine the response to therapy.
Study NCT01502956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox® injection
Description: Eligible subjects will complete baseline assessments, be randomized and scheduled for Botox A® injection visit. Subjects who received a Botox A® injection will be assessed for a clinical response, at 1 month from injection, using the same clinical criterion (≥50% improvement in the mean number of UUIE/day on a 3 day bladder diary completed prior to the 1 month visit). Those subjects that experience a clinical response, at one month, will be eligible for a repeat Botox A® injection after 6 months, if they experience degradation of clinical effect, using the PGSC.
Study NCT01909843 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0171
Description: Escalating dose of ALX-0171 during maximum 3 consecutive days: from 2.1 mg to maximum 200 mg per inhaled dose followed by daily dose of 70 mg, 140 mg or 200 mg per dose for maximum 4 consecutive days
Study NCT00753298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric Primo (POBE) single-use urinary catheter
Description: LoFric Primo (POBE) single-use urinary catheter
Study NCT00753298 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LoFric Primo (PVC) single-use urinary catheter
Description: LoFric Primo (PVC) single-use urinary catheter
Study NCT02510716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SGR
Study NCT02510716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support message only
Study NCT02510716 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support message only
Study NCT03015090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: After oral theophylline 200mg per day for one week, blood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2
Study NCT04529109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A investigational cosmetic lens 1
Description: TEST
Study NCT04529109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A investigational cosmetic lens 2
Description: CONTROL
Study NCT04297228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step by Step: A Family-Centered Healthy Lifestyle Intervention
Study NCT01623128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal video
Description: Participants are randomized to view either the intervention video or a sham video.
Study NCT01623128 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prenatal video
Description: Participants are randomized to view either the intervention video or a sham video.
Study NCT00989261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound AC220
Description: Precomplexed powder in bottle formulation supplied as 200 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
Study NCT01921426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419
Description: GC4419 is a novel, highly stable manganese-containing macrocyclic ligand complex with a molecular weight of 483, whose activity mimics that of naturally occurring superoxide dismutase (SOD) enzymes. It is therefore a prototype of a new class of drugs termed selective SOD mimetics. GC4419 selectively removes superoxide anions without reacting with other reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite.
Study NCT01968382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM 124-E (Hyperimmune Bovine Colostrum)
Description: Hyper-immune bovine colostrum enriched with anti-LPS antibodies and which has been designated by Immuron as IMM-124E.
Study NCT01968382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (High protein milk powder)
Description: Subjects will receive a total of 4 sachets (2 in the morning and 2 in the evening) daily
Study NCT01968382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (High protein milk powder)
Description: Subjects will receive a total of 4 sachets (2 in the morning and 2 in the evening) daily
Study NCT02745951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heliox
Description: Half of the study population will be randomly assigned to receive cardioplegia enriched with a 70:30 (Helium:Oxygen) via a D100 pediatric oxygenator. The Heliox itself will need to be administered via an oxygen regulator using a low flowmeter.
Study NCT02745951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: The other half will be randomized to Nitrogen:Oxygen mixture. This will be done through the standard of care cardioplegia apparatus. There will be no novel interventions administered in this group.
Study NCT04549064 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: diagnosis of pancreatic cancer
Description: Diagnosis of pancreatic cancer based on the concentration of serum biomarkers
Study NCT01624766 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Given SC
Study NCT01624766 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Given SC
Study NCT01624766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT04059796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omega Gemini III Rev 2 Device
Description: Eyes randomized to receive the Gemini III Rev 2 device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction
Study NCT04059796 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Eye
Description: Control eyes will receive an approved monofocal or toric IOL post cataract extraction
Study NCT03493737 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of life surveys
Description: Quality of life surveys by EQ-5D and QLQ-C30
Study NCT04219202 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton radiation
Description: Therapeutic radiation Treatment with Protons
Study NCT04219202 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon Ion radiation
Description: Therapeutic radiation Treatment with Carbon Ions
Study NCT01611090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Type=exact number, unit=mg, number=420 , form=capsule, route=oral use. Capsule is taken once daily continuously.
Study NCT01611090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine hydrochloride
Description: Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.
Study NCT01611090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bendamustine hydrochloride
Description: Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.
Study NCT01611090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.
Study NCT01611090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.
Study NCT01611090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=capsule, route=oral use. Capsule is taken once daily continuously.
Study NCT01829464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-875 placebo-matching tablets
Study NCT01829464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 tablets
Study NCT02850068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geniculate Artery Embolization
Description: Geniculate artery embolization (GAE) is a new procedure that is being used to reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA). Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the knee, resulting in improvement of pain, stiffness and difficulty performing daily activities from OA.
Study NCT00661999 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: Given by injection
Study NCT00661999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous sulfate
Description: Given by mouth
Study NCT00661999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium ferric gluconate complex in sucrose
Description: Given by IV
Study NCT00661999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given by mouth
Study NCT02238223 — intervention group
Intervention type: DRUG
Intervention: Alesion®
Study NCT02285127 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short versus long cephalomedullary Intramedullary nail
Description: Biomet Affixus Short and Long hip fracture nail. Stryker Gamma Short and Long hip fracture nail.
Study NCT01915732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duac™Once Daily Gel
Description: 1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide
Study NCT01915732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% clindamycin phosphate gel
Description: 1% clindamycin as clindamycin phosphate
Study NCT03352427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 60 mg/m2 orally twice daily
Study NCT03352427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 3.0 mg/m2, with titration of dosing after first cycle to keep trough level of 5-15 ug/ml
Study NCT00417690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Aminosalicylic acid
Description: Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
Study NCT00417690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PASER placebo granules
Description: Oral granules administered administered as one packet three times daily for two weeks followed by one packet two times daily for two weeks
Study NCT02716129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 38 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.2 mg morphine (Infumorph - Injection 10 mg/mL) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
Study NCT02716129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine plus Nalbuphine
Description: 39 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.5 mg morphine (Infumorph - Injection 10 mg/mL) plus 0.2 mg nalbuphine (NALUFIN 20MG/ML AMP) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
Study NCT01180595 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Trabecular Metal Modular Tibial Total Knee Component
Description: The modular design of the Trabecular Metal Total Knee allows for increased options for physicians however, it is not clear how this modular feature will affect fixation since it may compromise some of the advantages of the original TM Monoblock tibial component.
Study NCT01180595 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Trabecular Metal Monoblock Tibial Total Knee Component
Study NCT00617110 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: live attenuated influenza virus (LAIV) with clean air
Description: Allergic subjects will be exposed to air followed by administration of live attenuated influenza virus
Study NCT00617110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LAIV and diesel exhaust particles
Description: subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
Study NCT00617110 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: LAIV and diesel exhaust particles
Description: subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
Study NCT02419690 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: text message intervention
Description: Subjects will be sent 58 messages (3-5 per week) over 12 weeks, plus reminder messages for follow up interviews. The content of these messages will focus on contraception methods and effectiveness, sexually transmitted infection (STI) transmission, condom use, partner and parental communication, and healthy relationships. There will also be several text messages asking the participant if they would like to have a health educator contact them. The format will include facts, quizzes, true/false and some will have links to videos/pictures and websites, and some will request a response.
Study NCT01217086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab 3mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
Study NCT01018745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-907351 (XL184)
Description: Capsules, Oral, 25, 50, 75, 100, 125 and 175 mg, Once daily, Until disease progression or unacceptable toxicity became apparent
Study NCT04686708 — intervention group
Intervention type: OTHER
Intervention: Emergency general surgical admissions
Description: All emergency general surgical admissions are admitted initially to the emergency department and then referred to the general surgery department for further management (medical, interventional, or surgical approaches).
Study NCT01236625 — intervention group
Intervention type: PROCEDURE
Intervention: Adhesiolysis
Description: Blunt or sharp dissection of adhesive tissue.
Study NCT01973517 — intervention group
Intervention type: DRUG
Intervention: Feraheme
Description: Patients with relapsing remitting multiple sclerosis will be administered Feraheme 5mg/kg IV via slow push once and imaged under high-field MRI at least 24 hours following administration, to allow for adequate clearance of intravascular pharmaceutical.
Study NCT01973517 — intervention group
Intervention type: DRUG
Intervention: Gadolinium-based contrast
Description: Patients with relapsing remitting multiple sclerosis will be administered gadolinium-based contrast at a dose of 0.1 mmol/kg IV once and imaged under high-field MRI immediately following administration.
Study NCT06178042 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MI Paste Plus
Description: Briefly, a pea-sized amount of the cream was used once a day and was allowed to remain on the teeth for three minutes after conventional tooth brushing. Patient was advised to not to spit out the cream for 30 seconds to activate the product with saliva. Patient was advised to spit out the remaining amount to avoid swallowing excessive fluoride and to wait for 30 minutes after the treatment before rinsing or eating or drinking.
Study NCT06178042 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Remin Pro
Description: The cream must remain on the teeth for at least three minutes once daily after conventional tooth brushing. Patient was advised to spit out the remaining amount to avoid swallowing excessive fluoride and to wait for 30 minutes after the treatment before rinsing or eating or drinking.
Study NCT06178042 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients instructed to follow a routine home care.
Study NCT03625700 — intervention group
Intervention type: DRUG
Intervention: Oxygen gas
Description: Supplementary oxygen supplied via nasal catheter or oxygen mask during hospital admission.
Study NCT03222453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoetic stem cells
Description: Patient will inject with hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells
Study NCT02212925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 14332 CL
Study NCT02212925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03198429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring Dads
Description: Caring Dads is a 15-week group intervention program for fathers, with an intensive intake and two additional individual sessions to set and monitor specific, individualized change goals. Major aspects of innovation in the Caring Dads program include: the use of a motivational approach to engage and retain men in intervention; consistent emphasis on the need to end violence against children's mothers alongside of improving fathering; program content addressing accountability for past abuse and a model of collaborative practice with child protection. The Caring Dads program was developed with a specific commitment to remain focused on the safety and well-being needs of children as a primary goal of intervention and with the recognition that children's safety and well-being is integrally connected to that of their mothers.
Study NCT03198429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothers in Mind
Description: Mothers in Mind uses an attachment and trauma-informed psycho-educational process approach in 12 weekly sessions (10 of which are in group) with mothers. These sessions focus on raising awareness and validation about the experience of violence and the impact it has on mothering. Specifically, MIM increases mothers' awareness of the impact that exposure to family violence/trauma may have had on their infants and themselves as mothers, helps identify and promote positive parenting skills such as sensitivity and responsiveness to infant needs by increasing parental competence, helps promote emotional closeness and decreasing mothers' social isolation, increases mother and infant physical safety, and encourages positive attachment processes.
Study NCT03499106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1973
Description: Oral Tablet
Study NCT03499106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral Capsule
Study NCT00765739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: neuromuscular electrical stimulation that produce 40% of the maximum voluntary contraction
Study NCT00765739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: voluntary strengthening exercise
Description: contracting the quadriceps muscle voluntarily to produce 40% of maximum voluntary contraction
Study NCT03543176 — intervention group
Intervention type: OTHER
Intervention: UMEC/VI
Description: UMEC/VI as 62.5/25 mcg, which is a once-daily single inhaler dual therapy, given to subjects, via Ellipta .
Study NCT03543176 — intervention group
Intervention type: OTHER
Intervention: FLUT/SAL
Description: FLUT/SAL as 250/50 mcg, which is a twice-daily single inhaler dual therapy, given to subjects, via Diskus.
Study NCT03543176 — intervention group
Intervention type: OTHER
Intervention: CAT
Description: Questionnaire used to asses Condition-related well-being, for COPD subjects.
Study NCT03543176 — intervention group
Intervention type: OTHER
Intervention: mMRC
Description: Questionnaire used to asses Breathlessness, due to Dyspnea, for COPD subjects.
Study NCT03543176 — intervention group
Intervention type: DEVICE
Intervention: Ellipta
Description: It is a single once daily, Dry powder Inhaler (DPI), developed for delivery of therapies in COPD subjects.
Study NCT03543176 — intervention group
Intervention type: DEVICE
Intervention: Diskus
Description: It is a plastic device containing twice-daily single inhaler dual therapy, developed for delivery of therapies in COPD subjects.
Study NCT03911076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVX-2
Description: pNGVL4a-Sig/E7(detox)/HSP70 (pBI-1, naked DNA plasmid priming vaccine) TA-CIN (HPV16 L2E7E6 fusion protein booster vaccine)
Study NCT03911076 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PBS and PGC